Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow seems they are constantly finding something new regarding Brilacidins inherent abilities. BRL could end up a block buster in time. Having the government keep funding these studies is huge imo.
Oh I see the titles are there but the body of the release(s) is missing.
Example:
February 17, 2010
Cellceutix Completes Successful Pre-IND Meeting with FDA for Cancer Drug
Turns into the following when you try to open it.:
We couldn't find the page you were looking for. This is either because:
There is an error in the URL entered into your web browser. Please check the URL and try again.
The page you are looking for has been moved or deleted.
You can return to our homepage by clicking here, or you can try searching for the content you are seeking by clicking here.
Yes I am aware K was discontinued per the 10-k.
You can remove it from the drug pipeline like with prurisol but the data remains. The good thing is we have B which has super computer pedigree.
Not sure what he's looking at cause I just filtered in Kevetrin and I see the press releases are still there.
http://www.ipharminc.com/press-release select Kevetrin
Yes and early on Redesiver failed slid into a deep ditch was poo pooed by NIH but yet was pulled out and resurrected by big pharma and became soc.. B has gone on to kill viruses, bacteria and now fungi being more versatile them Rem owners could have dreamed. Now we wait on B nasal formulation to kill those nasty buggers in the airway BEFORE the viruses take hold.
The scientific investigators involved have all that put their real names on these papers. Also real government funding at work.
And along the way we get some nice price appreciation too!
Patents can be changed and updated depending on drug delivery method or an additive. Leo could have just left it on the shelf and not removed it all together. Seems Leo cleared the deck for a B only future. This testing is targeting many areas and could be a huge market opportunity. B is in the hands of professionals and I like that.
"BRI overcomes the CAS-acquired resistance in both A. fumigatus
and C. albicans and the CAS-intrinsic resistance in C. neoformans. BRI also
has an additive effect on the activity of posaconazole (POSA) against several
Mucorales fungi. Cell toxicity assays and fungal burden studies in an
immunosuppressed murine model of IPA showed that BRI combined with CAS
is not toxic to the cells and significantly clears A. fumigatus lung infection,
respectively. Our results indicate that combinations of BRI and antifungal drugs
in clinical use are likely to improve the treatment outcome of IPA and other
fungal infections".
I think this is a no brainer as an inhaler for hospital use. Fungal infections are a problem in hospitals.
They are throwing B at everything. So far positive results in antibiotic, anti-viral and anti-fungal. Multiple country's involved in this.
I think Leo is just supplying B to government labs and waiting on results. The development of a nasal formulation is where we are at now. I hope B's broad-spectrum ability is the ticket.
We await a completed B nasal formulation per GMU testing.
Well that's that then. B is yet being researched at least we have that. Four employees on the payroll?? Where's the beef?
Level 3 and 4 bio-labs are our national security and likely not concerned getting research dollars. B is being tested at GMU this we know.
I expect a nasal formulation to be completed soon. There has been a lot of good results lately regarding B's ability to kill many virus types.
"Brilacidin is thus able to exert a combined protective effect by decreasing both viral and inflammatory load" per George Mason University.
--Complete data ANAVEX®2-73 U.S. adult Rett syndrome (RTT) Phase 2 study
--Complete data ANAVEX®2-73 Parkinson’s disease dementia (PDD) Phase 2 study
--Top-line data Phase 1 ANAVEX®3-71 clinical trial
--Top-line data AVATAR: Potentially pivotal Phase 3 adult RTT ANAVEX®2-73 clinical trial
> Top-line data ANAVEX®2-73-AD-004: Potentially pivotal Phase 2b/3 AD clinical trial -- expected fall 2022
> Data of 48-week OLE PDD Phase 2 study – expected by end 2022
> EXCELLENCE completion: Potentially pivotal Phase 2/3 pediatric RTT clinical trial -- expected by end 2022
> Initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical trial – expected 2022
> Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 Fragile X clinical trial – expected 2022
> Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial for the treatment of a new, rare disease indication – expected 2022
> Initiation of ANAVEX®3-71 Phase 2 clinical trial for FTD, schizophrenias and Alzheimer’s disease – expected 2022
The company has multiple clinical milestones Catalysts to Drive Value
Page15
Waiting to hear more on dosing: Ongoing efforts are focused on dosing strategies for brilacidin to improve in vivo effectiveness in the form of a nasally-delivered countermeasure.
"NIAID will evaluate and ADVANCE new drug candidates to the stage of being late Phase 2-ready. NIAID will manufacture products and conduct Phase I/II trials. NIAID aims to attract industry partners and shorten the time frame from scientific discovery to licensure to application of effective public health tools."
I think this is where we are striving to now (ADVANCE new drug candidates to the stage of being late Phase 2-ready). We could likely see a nasal prophylactic version of B ready to go soon.
Dosing strategies for brilacidin to improve in-vivo effectiveness sure sounds like they are now getting it ready for human use. B kills viruses by contact could be a good fit as a nasal delivery.
"Several lines of evidence suggest that brilacidin may affect virion integrity and hence impact viral entry, thus positioning it well as a broad-spectrum prophylactic countermeasure solution".
Not even close.
"NIAID will evaluate and ADVANCE new drug candidates to the stage of being late Phase 2-ready. NIAID will manufacture products and conduct Phase I/II trials. NIAID aims to attract industry partners and shorten the time frame from scientific discovery to licensure to application of effective public health tools."
Sit back and let them run with it.
My opinion if Brilacidin meets it's potential as a broad-spectrum antiviral it may likely win approval in this current climate. We have strong reported evidence so far of B's anti-viral capabilities. The nasal application as an early treatment looks to be a good fit. We wait and see.
“Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses.”
Across multiple cell lines and under different testing conditions, research showed Brilacidin inhibited viral replication in a statistically significant manner in encephalitic alphaviruses, including Venezuelan Equine Encephalitis Virus (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Sindbis Virus (SINV). Brilacidin also was shown to inhibit Rift Valley Fever Virus (RVRF), a contagious bunyavirus that can lead to blindness, liver failure, and hemorrhagic fever in infected individuals. Moreover, anti-inflammatory activity was observed, indicating intracellular events are modulated by Brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing viral and inflammatory load.
Or perhaps even as a spray like Chloraseptic. Feel that icky feeling in your throat hit it with Brila. Looking forward to the finished dosing studies.
"The observations that we continue to make in experiments involving brilacidin in the context of acutely infectious viruses support the idea of brilacidin functioning in a broad-spectrum capacity as an antiviral compound"
Could work on cats too. Let's wait and see.
Brilacidin is now in a nasal administered anti-viral going through dose strategy testing in-vivo.
This new development by George Mason University if successful could be an early treatment against influenza. Go B
So we now know we have a nasal administered anti-viral going through dose strategy testing in-vivo.
Viruses generally enter into the upper airways and nose just by breathing or touching ones face and in doing so viral replication begins. My take is since B kills viruses by contact seems a perfect early treatment route.
If B keeps proving out as a broad spectrum anti-viral it may also work well as a onset treatment against nasty cold viruses.
This from the George Mason university attachment (conclusion) is huge in the aspect that there is now a nasal form of B being tested tweaked for in vivo effectiveness in other words in the body of a living organism.
"Brilacidin is thus able to exert a combined protective effect by decreasing both viral and inflammatory load. Brilacidin has undergone several clinical studies as treatment for bacterial infections. Ongoing efforts are focused on dosing strategies for brilacidin to improve in vivo effectiveness in the form of a nasally-delivered countermeasure.
https://static1.squarespace.com/static/5715352e20c647639137f992/t/63226423ad15bb3c77223340/1663198243904/MHSRS2022+-+Brilacidin+poster+fv.pdf
An anti-viral nasal application would likely be a financial game changer and we know from reports they are working on it.
Agree formulation is complete and now they are just tweaking the amounts. Not to sound trivial but it's likely B mixed in sterilized water with some sort of stabilizer then put into a spray bottle how hard can that be.
I agree we are likely soon to see a nasal version of Brilacidin developed for onset use as a broad spectrum anti-viral treatment.
Per George Mason university- Brilacidin is thus able to exert a combined protective effect by decreasing both viral and inflammatory load.
This is something new. I believe this is the first reported study on a "non-enveloped" virus and again Brilacidin showed anti-viral activity. Non- Enveloped viruses could open a whole other world of treatments.
The in vitro evaluation of Brilacidin's antiviral activity was expanded to Echovirus, a non-enveloped picornavirus, to assess Brilacidin's effect on early viral entry in contrast to its ability to disrupt the lipid membranes of enveloped viruses. Brilacidin was shown to inhibit Echovirus, suggesting Brilacidin possesses additional antiviral mechanisms beyond its ability to directly impact viral envelopes.
Funding news and maco agents will have their work cut out for them. A so small voice in the wilderness.
IPIX's new investment has a nice website.
https://www.beam-med.com/
Could be reasons to hold information quiet, possibly at behest of the other company.
Quite possible the completed payer analysis reported in July cleared the way for a deal. Gone quiet on this ever since.
I know what you mean but covid-19 likely killed two years progress. If not more as governments put all efforts to bear on covid.
Yes a good ending for us all. But you can't live by bread alone:)
Should be past the finish line. Payer Analysis was reported July22. Leo needs to address shareholders.smh